Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: Increased plasma factor VII and X activities and D-dimer levels

Experimental and Clinical Endocrinology and Diabetes

Volumn 116, Issue 10, 2008, Pages 619-624

  Erem, C ^a   Kocak, M ^a   Hacihasanoglu, A ^a   Yilmaz, M ^a   Saglam, F ^a   Ersoz, H O ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Coagulation; Fibrinolysis; Lipid profile; Primary hyperparathyroidism

Indexed keywords

ALKALINE PHOSPHATASE; ANTITHROMBIN III; APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CALCIUM; CHOLESTEROL; D DIMER; FIBRINOGEN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHORUS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; LIPID BLOOD LEVEL; MALE; MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE COUNT; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 57049106865     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1065365     Document Type: Article

References (58)

1. Andersson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart disease-a review. Eur Heart J 2004; 25: 1776-1787
2. Hedback G, Oden A. Increased risk of death from primary hyperparathyroidism-an update. Eur J Clin Invest 1998; 28: 271-276
3. Kiernan TJ, O'Flynn AM, MacDermott JH, Kearney P. Primary hyperparathyroidism and the cardiovascular system. Int J Cardiol 2006; 113: E89-E92
4. Rapado A. Arterial hypertension and primary hyperparathyroidism. Incidence and follow-up after parathyroidectomy. Am J Nephrol 1986; 6 (Suppl 1): 49-50
5. Piovesan A, Molineri N, Casasso F, Emmolo I, Ugliengo G, Cesario F, Borretta G. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf) 1999; 50: 321-328
6. Stefenelli T, Abela C, Frank H, Koller-Strametz J, Globits S, Bergler-Klein J, Niederle B. Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. J Clin Endocrinol Metab 1997; 82: 106-112
7. Baykan M, Erem C, Erdogan T, Hacihasanoglu A, Gedikli O, Kiris A, Kucukosmanoglu M, Ersoz HO, Celik S. Impairment of flow mediated vasodilatation of brachial artery in patients with primary hyperparathyroidism. Int J Cardiovasc Imaging 2007; 23: 323-328
8. Kosch M, Hausberg M, Vormbrock K, Kisters K, Rahn KH, Barenbrock M. Studies on flow-mediated vasodilation and intima-media thickness of the brachial artery in patients with primary hyperparathyroidism. Am J Hypertens 2000; 13: 759-764
9. Chadwick DR, Harrison BJ, Chan P, Chong L, Peachell P. Vasoactive and proliferative effects of parathyroid hormone and parathyroid hormone-related peptide on human vascular smooth muscle. Br J Surg 2000; 87: 1529-1533
10. Lind L, Ljunghall S. Serum calcium and the ECG in patients with primary hyperparathyroidism. J Electrocardiol 1994; 27: 99-103
11. Procopio M, Magro G, Cesario F, Piovesan A, Pia A, Molineri N, Borretta G. The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed type 2 diabetes mellitus in primary hyperparathyroidism. Diabet Med 2002; 19: 958-961
12. Hagstrom E, Lundgren E, Lithell H, Berglund L, Ljunghall S, Hellman P, Rastad J. Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: population-based study over five years. Clin Endocrinol (Oxf) 2002; 56: 253-260
13. Grey AB, Evans MC, Stapleton JP, Reid IR. Body weight and bone mineral density in postmenopausal women with primary hyperparathyroidism. Ann Intern Med 1994; 121: 745-749
14. Westerdahl J, Valdemarsson S, Lindblom P, Bergenfelz A. Urate and arteriosclerosis in primary hyperparathyroidism. Clin Endocrinol (Oxf) 2001; 54: 805-811
15. Wermers RA, Khoslo S, Atkinson EJ, Grant CS, Hodgson SF, O'Fallon WM, Melton LJ. Survival after the diagnosis of hyperparathyroidism: a population-based study. Am J Med 1998; 104: 115-122
16. Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone levels predict coronary heart disease: the Tromso Study. Eur J Cardiovasc Prev Rehabil 2004; 11: 69-74
17. Fallo F, Camporese G, Capitelli E, Andreozzi GM, Mantero F, Lumachi F. Ultrasound evaluation of carotide artery in primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88: 2096-2099
18. Lumachi E, Ermani M, Luisetto G, Nardi A, Basso SMM, Camozzi V, Favia G. Relationship between serum parathyroid hormone, serum calcium and arterial blood pressure in patients with primary hyperparathyroidism: results of a multivariate analysis. Eur J Endocrinol 2002; 146: 643-647
19. Tzoulaki I, Murray GD, Price JF, Smith FB, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Hemostatic factors, inflammatory markers, and progressive peripheral atherosclerosis: the Edinburgh Artery Study. Am J Epidemiol 2006; 163: 334-341
20. Haverkate F. Levels of haemostatic factors, arteriosclerosis and cardiovascular disease. Vascul Pharmacol 2002; 39: 109-112
21. Fibrinogen Studies Collaboration. Collaborative meta-analysis of prospective studies of plasma fibrinogen and cardiovascular disease. Eur J Cardiovasc Prev Rehabil 2004; 11: 9-17
22. Danesh J, Whincup P, Walker M et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001; 103: 2323-2327
23. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397
24. Lowe GD, Danesh J, Lewington S et al. Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 2004; 25: 252-259
25. Hueper W. Metastatic calcifications in the organs of the dog after injections of parathyroid extract. Arch Pathol 1927; 3: 14-25
26. Hilgard P, Hohage R, Schmitt W, Kohle W. Microangiopathic haemolytic anaemia associated with hypercalcaemia in an experimental rat tumour. Br J Haematol 1973; 24: 245-254
27. Hilgard P. Experimental hypercalcaemia and whole blood clotting. J Clin Pathol 1973; 26: 616-619
28. Remuzzi G, Benigni A, Dodesini P, Schieppati A, Livio M, Poletti E, Mecca G, Gaetano G de. Parathyroid hormone inhibits human platelet function. Lancet 1981; 2: 1321-1323
29. Leithner C, Kovarik J, Sinzinger H, Woloszczuk W. Parathyroid hormone does not inhibit platelet aggregation. Lancet 1984; 1: 367-368
30. Girolami A, Simioni P, Scarano L, Girolami B. Venous and arterial thrombophilia. Haematologica 1997; 82: 96-100
31. Silverberg SJ, Bilezikian JP. Cytokines in primary hyperparathyroidism-factors that matter. J Clin Endocrinol Metab 1996; 81: 3448-3449
32. Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, Widder W, Molnar C, Ludwiczek O, Atkins MB, Mier JW, Tilg H. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001; 98: 2720-2725
33. Feinbloom D, Bauer KA. Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol 2005; 25: 2043-2053
34. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-537
35. Junker R, Heinrich J, Schulte H, Loo J van de, Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol 1997; 17: 1539-1544
36. Broadhurst P, Kelleher C, Hughes L, Imeson JD, Raftery EB. Fibrinogen, factor VII clotting activity and coronary artery disease severity. Atherosclerosis 1990; 85: 169-173
37. Ruddock V, Meade TW. Factor VII activity and ischaemic heart disease: fatal and non-fatal events. QJM 1994; 87: 403-406
38. Heinrich J, Balleisen L, Schulte H, Assmann G, Loo J van de. Fibrinogen and factor VII in the prediction of coronary risk Results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14: 54-59
39. Folsom AR, Wu KK, Shahar E, Davis CE. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Arterioscler Thromb 1993; 13: 1829-1836
40. Vaziri ND, Kennedy SC, Kennedy D, Gonzales E. Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction and angina pectoris. Am J Med 1992; 93: 651-657
41. Simpson HCR, Mann JI, Meade TW, Chakrabarti R, Stirling Y, Woolf N. Hypertriglycerideamia and hypercoagulability. Lancet 1983; 1: 786-790
42. Zitoun D, Bara L, Basdevant A, Samama MM. Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias. Arterioscler Thromb Vasc Biol 1996; 16: 77-81
43. a in hyperlipidaemia, with possible implications for ischaemic heart disease. Br J Haematol 1985; 59: 249-258
44. Sousa JC de, Soria C, Ayrault-Jarrier M, Pastier D, Bruckert E, Amiral J, Bereziat G, Caen JP. Association between coagulation factors VII and X with triglyceride rich lipoproteins. J Clin Pathol 1988; 41: 940-944
45. Negri M, Arigliano PL, Talamini G, Carlini S, Manzato F, Bonadonna G. Levels of plasma factor VII and factor VII activated forms as a function of plasma trigylceride levels. Atherosclerosis 1993; 99: 55-61
46. Hoffman CJ, Lawson WE, Miller RH, Hultin MB. Correlation of vitamin K-dependent clotting factors with cholesterol and trigylcerides in healthy young adults. Arterioscler Thromb 1994; 14: 1737-1740
47. Okura Y, Hayashi K, Shingu T, Kuga Y, Nomura S, Kajiyama G, Nakashima Y, Keijiro S. Angiotensin-converting enzyme insertion/deletion genotype is associated with the activities of plasma coagulation factor VII and X independent of triglyceride metabolism. Coranary Artery Dis 2003; 14: 285-291
48. Gasic GP, Arenas CP, Gasic TB, Gasic GJ. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci USA 1992; 89: 2317-2320
49. Koo BH, Chung KH, Hwang KC, Kim DS. Factor Xa induces mitogenesis of coronary artery smooth muscle cell via activation of PAR-2. FEBS Lett 2002; 523: 85-89
50. Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D, Greenberg H, Weiss HJ, Zareba W, Brown MW, Liang CS, Lichstein E, Little WC, Gillespie JA, Voorhees L Van, Krone RJ, Bodenheimer MM, Hochman J, Dwyer Jr EM, Arora R, Marcus FI, Watelet LF, Case RB. Thrombogenic factors and recurrent coronary events. Circulation 1999; 99: 2517-2522
51. Smith EB, Thompson WD. Fibrin as a factor in atherogenesis. Thromb Res 1994; 73: 1-19
52. Tataru MC, Heinrich J, Junker R, Schulte H, Eckardstein A von, Assmann G, Koehler E. D-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. Eur Heart J 1999; 20: 1493-1502. Comment in: Eur Heart J. 1999: 20: 1443-44.
53. Morishita E, Jokaji H, Matsuda T. Hyperlipidemia and hemostatic system. J Atheroscler Thromb 1995; 2 (Suppl 1): S36-40
54. Thomas DP, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med 1997; 126: 638-644
55. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G. High plasminogen activator inhibitor and tissue plasmin activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-2247
56. Bonom E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998; 47: 1643-1649
57. Garcia de la Torre N, Wass JA, Turner HE. Parathyroid adenomas and cardiovascular risk. Endocr Relat Cancer 2003; 10: 309-322
58. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. National Cholesterol Education Program National Heart, Lung, and Blood Institute National Institutes of Health NIH Publication No. 02-5215 September 2002